Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.
The expression of monomorphic determinants of the histocompatibility leukocyte antigens (HLA) class I antigens by human malignant tumor cells was studied in tissue specimens of 70 primary tumor lesions obtained from patients with carcinoma of the breast (41 patients), colon (8 patients), urinary bladder (8 patients), and kidney (13 patients), and in samples of either synchronous or metachronous lymph node, lung, or liver metastases available in 44 of the patients. The frequencies of HLA class I expressor and nonexpressor tumor cells were determined by immunohistochemical staining of histological sections of fresh frozen tissue samples with the W6/32 monoclonal antibody. The tumor cell populations in the majority of the primary lesions consisted predominantly of HLA-immunoreactive cells (observed in 38 of 70 patients; 54%), especially in those patients who did not have clinical evidence of metastatic disease (8 of 11 patients; 73%). Various degrees of loss of reactivity were observed in other primary lesions, although in only 8 (12%) tumors (7 of which were obtained from patients with metastatic disease), the neoplastic cells were nearly exclusively HLA-nonreactive. In contrast, the majority of metastatic lesions consisted of either predominantly HLA-negative cells (33 of 44 specimens; 75%) or mixed populations (10 of 44 specimens; 23%), whereas only one metastatic lesion manifested HLA class I antigen staining in more than 70% of its tumor cells (P = 0.0005). Intravascular clusters of tumor cells consisted predominantly of HLA class I nonexpressors. The observed patterns of distribution of HLA expressors and nonexpressor tumor cells are compatible with the notion that HLA-negative cells in human carcinomas manifest a selective advantage with regard to metastatic progression and growth. The suppressed expression of major histocompatibility complex class I antigens on metastatic cells may lead to failure of presentation of cell surface tumor specific epitopes to host cytotoxic T-lymphocytes. Such a process would enable tumor cells to evade host immune responses and would promote and enhance cell dissemination and metastatic growth.
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
C
C
Cordon-Cardo
Z
Z
Fuks
M
M
Drobnjak
C
C
Moreno
L
L
Eisenbach
M
M
Feldman
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D001940:Breast / Q000276:immunology; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology; D003106:Colon / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology; D015234:HLA-A Antigens / Q000032:analysis*; D015235:HLA-B Antigens / Q000032:analysis*; D015236:HLA-C Antigens / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D007668:Kidney / Q000276:immunology; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000276:immunology*; D009360:Neoplastic Cells, Circulating / Q000276:immunology; D001743:Urinary Bladder / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens